PB1878: CROSS‐TRIAL ANALYSIS OF FIXED‐DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Authors :: Barrientos, J. C.
Barr, P. M.
Mato, A. R.
Tam, C. S.
Ghia, P.
Moreno, C.
Kay, N. E.
Siddiqi, T.
Szafer‐Glusman, E.
Zhou, C.
Neumayr, L.
Krigsfeld, G.
Wierda, W. G.
Shanafelt, T.
Source :: HemaSphere; 2022 Supplement 3, Vol. 6, p1758-1759, 2p
Publication Year :: 2022

Full Text Access

Tools